022 Prnewswire Telix Pharmaceuticals Limited Asx Tlx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from 022 prnewswire telix pharmaceuticals limited asx tlx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In 022 Prnewswire Telix Pharmaceuticals Limited Asx Tlx Today - Breaking & Trending Today

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% positive predictive value (secondary endpoint) considerably exceeding sensitivity and specificity targets These ground-breaking results indicate that TLX250-CDx has the potential to become a new clinical standard in the diagnosis of ccRCC and deliver an unmet medical need for a non-invasive diagnostic tool in this disease setting Based on these positive results, Telix will progress towards a Biologics License Application (BLA) filing with the U.S. Food and Drug Administration (FDA) and worldwide regulatory filings in key commercial jurisdictions MELBOURNE, Australia, Nov. 7, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces highly positive top-line results fr ....

United States , United Kingdom , Los Angeles , Gregory Jack , Kyahn Williamson , Colin Hayward , Francoise Kraeber Bodere , Brian Shuch , Telix Pharmaceuticals , Urological Surgeon Austin Health , Drug Administration , Institute Of Urologic Oncology Los Angeles , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Kidney Cancer Program , Olivia Newton John Cancer Centre Melbourne , Corporate Communications , Health Canada , Nuclear Medicine Department , Biologics License Application , Pharmaceuticals Limited , Prof Brian Shuch , Urologic Oncology , General Urological Surgeon Austin Health , Olivia Newton John Cancer Centre ,

Telix Acquires Optimal Tracers

MELBOURNE, Australiaand INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials. The acquisition of Optimal Tracers will bolster Telix's in-house radiochemistry development capability, by adding a highly skilled team to Telix and establishing a U.S.-based laboratory and production footprint for clinical trial doses. The acquisition includes a facilitywith a radiation and pharmaceutical manufacturing licence sufficient to cover the Company's key diagnostic and therapeutic isotope requirements for pre-clinical and clinical research purposes. The acquisition of Optimal Tracers aligns with Telix's strategy to build a degree of vertical inte ....

United States , United Kingdom , Kyahn Williamson , Jonathan Barlow , Ruth Tesar , University Of California , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Imaging Center , Corporate Communications , Global Business Development Alliance Management , Health Canada , Pharmaceuticals Limited , Sacramento Based Northern California , Optimal Tracers , West Coast , Business Development , Alliance Management , Optimal Tracer , Northern California , Telix Pharmaceuticals Limited , Ustraliaand Indianapolis , Nov 14 ,

Telix to Present at Jefferies London Healthcare Conference 2022

MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company),a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that Dr Christian Behrenbruch, Group CEO and Managing Director, will be presenting at the Jefferies London Healthcare Conference 2022. The presentation will take place on Thursday 17 November from 3:15 - 3:45pm GMT (10:15 - 10:45am EST / 2:15 - 2:45am AEDT, 18 Nov). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff255/tlx/1728648 The webcast will be accessible on demand on the Telix website following the event. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United ....

United States , Kyahn Williamson , Christian Behrenbruch , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Australian Therapeutic Goods Administration , Corporate Communications , Telix Pharmaceuticals Limited , Health Canada , Managing Director , Jefferies London Healthcare Conference , Group Chief Executive , Nov 11 , 022 Prnewswire Telix Pharmaceuticals Limited Asx Tlx , The Company , A Commercial Stage Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic Therapeutic Radiopharmaceuticals , Dvises That Dr Christian Behrenbruch , Group Ceo And Managing Director , Ill Be Presenting At The Jefferies London Healthcare Conference 2022 Presentation Will Take Place On Thursday 17 November From 3 15 45pm Gmt 10 45am Est 2 Aedt , 8 Nova Live Webcast Of The Presentation Will Be Available At Following Link Https Wsw Com Jeff255 Tlx 1728648 Accessible On Demand Telix Website Event About Pharmaceuticals Limited Isa Biopharmaceutical Company Focused Development And Commercialisation Diagnostic Therapeutic Radiopharmaceuticals Is Headquartered In Melbourne , Ustralia With International Operations In The United States , Urope Belgium And Switzerland , Nd Japan Telix Is Developinga Portfolio Of Clinical Stage Products That Aims To Address Significant Unmet Medical Need In Oncology And Rare Diseases Listed On The Australian Securities Exchange Asx Tlx For More Information Visit Www Telixpharma Comand Follow Twitter Linkedin 39s Lead Product , Allium 68 68ga Gozetotide Also Known As Psma 11 Injection , As Been Approved By The Us Food And Drug Administration Fda ,

Telix to Present at Jefferies London Healthcare Conference 2022

MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company),a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that Dr Christian Behrenbruch, Group CEO and Managing Director, will be presenting at the Jefferies London Healthcare Conference 2022. The presentation will take place on Thursday 17 November from 3:15 - 3:45pm GMT (10:15 - 10:45am EST / 2:15 - 2:45am AEDT, 18 Nov). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff255/tlx/1728648 The webcast will be accessible on demand on the Telix website following the event. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United ....

United States , Kyahn Williamson , Christian Behrenbruch , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Australian Therapeutic Goods Administration , Corporate Communications , Telix Pharmaceuticals Limited , Health Canada , Managing Director , Jefferies London Healthcare Conference , Group Chief Executive , Nov 11 , 022 Prnewswire Telix Pharmaceuticals Limited Asx Tlx , The Company , A Commercial Stage Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic Therapeutic Radiopharmaceuticals , Dvises That Dr Christian Behrenbruch , Group Ceo And Managing Director , Ill Be Presenting At The Jefferies London Healthcare Conference 2022 Presentation Will Take Place On Thursday 17 November From 3 15 45pm Gmt 10 45am Est 2 Aedt , 8 Nova Live Webcast Of The Presentation Will Be Available At Following Link Https Wsw Com Jeff255 Tlx 1728648 Accessible On Demand Telix Website Event About Pharmaceuticals Limited Isa Biopharmaceutical Company Focused Development And Commercialisation Diagnostic Therapeutic Radiopharmaceuticals Is Headquartered In Melbourne , Ustralia With International Operations In The United States , Urope Belgium And Switzerland , Nd Japan Telix Is Developinga Portfolio Of Clinical Stage Products That Aims To Address Significant Unmet Medical Need In Oncology And Rare Diseases Listed On The Australian Securities Exchange Asx Tlx For More Information Visit Www Telixpharma Comand Follow Twitter Linkedin 39s Lead Product , Allium 68 68ga Gozetotide Also Known As Psma 11 Injection , As Been Approved By The Us Food And Drug Administration Fda ,

Telix Acquires Optimal Tracers

MELBOURNE, Australiaand INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials. The acquisition of Optimal Tracers will bolster Telix's in-house radiochemistry development capability, by adding a highly skilled team to Telix and establishing a U.S.-based laboratory and production footprint for clinical trial doses. The acquisition includes a facilitywith a radiation and pharmaceutical manufacturing licence sufficient to cover the Company's key diagnostic and therapeutic isotope requirements for pre-clinical and clinical research purposes. The acquisition of Optimal Tracers aligns with Telix's strategy to build a degree of vertical inte ....

United States , United Kingdom , Kyahn Williamson , Jonathan Barlow , Ruth Tesar , University Of California , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Imaging Center , Corporate Communications , Global Business Development Alliance Management , Health Canada , Pharmaceuticals Limited , Sacramento Based Northern California , Optimal Tracers , West Coast , Business Development , Alliance Management , Optimal Tracer , Northern California , Telix Pharmaceuticals Limited , Ustraliaand Indianapolis , Nov 14 ,